Cas:80118-10-1 4-methylpent-4-en-2-yl 2-hydroxybenzoate manufacturer & supplier

Chemical Name:4-methylpent-4-en-2-yl 2-hydroxybenzoate

CAS.NO:80118-10-1

Synonyms:Benzoic acid,2-hydroxy-,1,3-dimethyl-3-buten-1-yl ester;EINECS 279-400-4;Benzoic acid,2-hydroxy-,1,3-dimethyl-3-butenyl ester;1,3-Dimethyl-3-butenyl salicylate

Molecular Formula:C₁₃H₁₆O₃

Molecular Weight:220.26400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:319.3ºC at 760 mmHg

Density:1.037g/cm3

Index of Refraction:1.506

PSA:46.53000

Exact Mass:220.11000

LogP:2.90370

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzoic acid,2-hydroxy-,1,3-dimethyl-3-buten-1-yl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-Dimethyl-3-butenyl salicylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 279-400-4 Use and application,Benzoic acid,2-hydroxy-,1,3-dimethyl-3-butenyl ester technical grade,usp/ep/jp grade.

Related News: The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. 4-methylpent-4-en-2-yl 2-hydroxybenzoate manufacturer This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 4-methylpent-4-en-2-yl 2-hydroxybenzoate supplier This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 4-methylpent-4-en-2-yl 2-hydroxybenzoate vendor “Whenever a company hires outside counsel to conduct an inquiry, it’s taken extremely seriously by the Justice Department,” said Paul Pelletier, a former long-time federal prosecutor who used to oversee criminal investigations of corporations. 4-methylpent-4-en-2-yl 2-hydroxybenzoate factory Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue.